Written question asked by David Anderson (Labour) on Friday, 3 June 2016, in the House of Commons. It was due for an answer on Tuesday, 7 June 2016. It was answered by George Freeman (Conservative) on Friday, 10 June 2016 on behalf of the Department of Health.
Muscular Dystrophy: Drugs
- Question
-
To ask the Secretary of State for Health, pursuant to the Answer of 25 May 2016 to Question 37646, what preparatory work NHS England is undertaking on Translarna; and whether a date has been set for a commercial meeting between NHS England and PTC Therapeutics after that preparatory work.
- Answer
-
Further to the answer given in Question 37646, NHS England has been undertaking the detailed preparatory work required to meet the National Institute of Health and Care Excellence’s request that NHS England and the supplier, PTC Therapeutics, work towards agreeing an acceptable managed access arrangement for Translarna (ataluren) by 7 July 2016.
NHS England will be meeting with the supplier when it has concluded this preparatory work. There have not been any commercial meetings with PTC Therapeutics in the period since 15th April 2016 - however, NHS England is in regular contact with the supplier and will be agreeing mutually convenient times to meet.
Secondary information
- Type
- Written question
- Reference
- 39182
- Session
- 2016-17
- Related items
- Subjects
- Drugs Prices Muscular dystrophy Ataluren PTC Therapeutics
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2020-11-05 09:08:48 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/39182
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/39182
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/39182